- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06187246
Avatar-based Therapy for Female Orgasmic Disorder
An Avatar-based Intervention in Second Life for Female Orgasmic Disorder: A Randomized Control Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Madrid
-
Alcorcon, Madrid, Spain, 28922
- Rey Juan Carlos University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Present the characteristics to diagnose female orgasm disorder after a clinic assessment (considering natural characteristics of the women's sexual response cycle (Conn & Hodges, 2022) based on the DSM-5 criteria.
- Provide a medical check to prove the absence of physical factors that may be the cause of the orgasm dysfunction, as this is the first part to diagnose FOD.
- Be at least 18 years old (adult).
- Have access to a computer with the characteristics to run Second Life and internet connection.
Exclusion Criteria:
- Present a diagnosis of a physical condition that may be the cause of the orgasm dysfunction (e.g., genital lesions, systemic and hormonal factors, vulvovaginal atrophy).
- Presence of other psychological pathology (e.g., depression, trauma) that may be the cause of the orgasm dysfunction.
- Have alcohol dependence (i.e., evaluated during the clinical assessment, according to the diagnostic criteria from the DSM-5, to determine if the individual meets the criteria for an alcohol use disorder diagnosis).
- Drug use, including medication that is known to cause sexual difficulties (e.g., selective serotonin reuptake inhibitors (SSRIs), that are a particularly common drug cause of sexual dysfunction.
- Have participated in a previous psychological intervention in the last year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Avatar-based Intervention Group
Treatment was based on the CBT approach and previous literature about FOD.
It consisted of 12 weekly online individual sessions, which were administered once a week (total duration = 3 months) and lasted about 60 minutes each.
|
Intervention was aimed at improving sexual variables (sexual satisfaction, sexual function, and initiative and sexual communication), and variables that are known to affect orgasm consecution (sexual self-esteem, sex-guilt, and sexual anxiety). To achieve this objective, it focused on fostering participants' abilities to increase their levels of sexual stimulation, and the engagement in personal values, along with identifying and modifying dysfunctional thoughts about sexuality. The techniques used included psychosexual education, cognitive restructuring, virtual exposure, sexual stimulation, and engagement in personal values from the acceptance and commitment therapy (ACT) perspective. It was delivered via a metaverse: Second Life. |
|
Active Comparator: Minimal support control group
It consisted in individual informative talks, during which they were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure).
Participants received three individual sessions once a month, and had a duration of one hour.
|
Participants were provided with information about female orgasm (e.g., what is an orgasm, neuronal orgasm, factors that may influence consecution, sexual response), masturbatory techniques (e.g., key elements to achieve pleasure, anatomy of the female genitalia, pleasure areas) and techniques to focus attention on one's body (i.e., an important factor to pleasure).
Participants received three individual sessions once a month, and had a duration of one hour.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sexual satisfaction assessed by the Golombok Rust Inventory of Sexual Satisfaction
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Sexual satisfaction is the feeling of pleasure that one has when the sexual desire has been fulfilled. The Golombok Rust Inventory of Sexual Satisfaction has minimum-maximum values of 0-112; higher scores mean a worse outcome. The cut-off for determining significant levels of Sexual Satisfaction is 60 (scores equal to or above 60 indicate the existence of a sexual problem). |
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
|
Sexual functionassessed by the Female Sexual Function Index
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Sexual function refers to the capacity of having a satisfactory sexual life.
The Female Sexual Function Index has minimum-maximum values of 19-95; higher scores mean a better outcome.
The cut-off for determining significant levels of this variable is 55 (scores equal to or below 55 indicate poor Sexual Function).
|
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
|
Initiative and Sexual Communication assessed by the Female Sexual Function Questionnaire
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Initiative and Sexual Communication is the proactive and consensual expression of one's sexual desires, interests, and intentions within the context of a sexual relationship or encounter. The Female Sexual Function Questionnaire has minimum-maximum values of 14-70; higher scores mean a better outcome. The cut-off for determining significantly low levels of this variable are scores equal to or lower than 25. |
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sexual self-esteem assessed by the Rosenberg Self-Esteem Scale
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Self-esteem related to sexuality; may influence on the consecution of orgasms.
The Rosenberg Self-Esteem Scale has minimum-maximum values of 10-40; higher scores mean a better outcome.
The cut-off for clinical low self-esteem is a score equal to or lower than 25.
|
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
|
Sex-guilt assessed by the Brief Mosher Sex-Guilt Scale
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Sex-guilt related to sexuality; may influence on the consecution of orgasms.
The Brief Mosher Sex-Guilt Scale has minimum-maximum values of 10-60; higher scores mean a worse outcome (higher scores indicate higher levels of guilt).
|
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
|
Sexual anxiety by the Sexual Anxiety scale of the Expanded Sexual Arousability Inventory
Time Frame: From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Sexual anxiety related to sexualiaty; may influence on the consecution of orgasms. TheSexual Anxiety scale of the Expanded Sexual Arousability Inventory has minimum-maximum values of 0-168; higher scores mean a worse outcome (higher scores indicate higher levels of sexual anxiety). |
From baseline to the end of the treatment at 12 weeks + 1 month-follow-up and 3 month-follow-up
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UniversidadRJC 2005202114121
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Orgasmic Disorder
-
Acerus Pharmaceuticals CorporationCompletedFemale Orgasmic DisorderUnited States, Canada, Australia
-
Center for Vulvovaginal DisordersUnknownFemale Orgasmic DisorderUnited States
-
S1 Biopharma, Inc.Not yet recruitingOrgasmic Disorder
-
Segraves, R., T., M.D., Ph.D.GlaxoSmithKlineCompleted
-
University of Texas at AustinEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMajor Depressive Disorder | Post-traumatic Stress Disorder | Hypoactive Sexual Desire Disorder | Female Orgasmic Disorder | Female Sexual Arousal DisorderUnited States
-
Hannover Medical SchoolCompletedSexual Arousal Disorder | Orgasmic Disorder | Restless Genital Syndrome | Psychosexual DisorderGermany
-
Cedars-Sinai Medical CenterCompletedUrinary Incontinence | Sexual Dysfunction | Pelvic Organ Prolapse | Pelvic Floor Disorders | Interstitial Cystitis | Female Sexual Dysfunction | Hypoactive Sexual Desire Disorder | Sexuality | Orgasmic Disorder | Sexual Desire DisorderUnited States
-
Procare Health Iberia S.L.WithdrawnFemale Sexual Interest/Arousal DisorderSpain
-
Biozeus Biopharmaceutical S.A.RecruitingFemale Sexual Dysfunction | Female Sexual Arousal DisorderBrazil
-
Biozeus Biopharmaceutical S.A.Not yet recruitingFemale Sexual Arousal Disorder | Female Sexual Dysfunction (FSD)Brazil
Clinical Trials on Avatar-based intervention
-
Ciusss de L'Est de l'Île de MontréalActive, not recruitingPsychotic Disorders | Mental Health Disorder | Cannabis Use DisorderCanada
-
Ciusss de L'Est de l'Île de MontréalCanadian Institutes of Health Research (CIHR)RecruitingPsychotic Disorders | Mental Health Disorder | Cannabis Use DisorderCanada
-
University of Southern CaliforniaUniformed Services University of the Health Sciences; Blue Star Families; Wilcox...CompletedQuality of Life | Communication | Social Skills | Mental Health Disorder | Social Isolation | Military FamilyUnited States
-
Le.L.A.T. Lega Lotta Aids E TossicodipendenzaCatholic University of the Sacred HeartCompletedSubstance Use Disorder (SUD)Italy
-
Yale UniversityAmerican Heart AssociationSuspended
-
Saint-Joseph UniversityRecruitingAnxiety | Local Anesthesia | Fear | Pediatric DentistryLebanon
-
Akdeniz UniversityThe Scientific and Technological Research Council of TurkeyCompletedDeveloping the ABEP-H | Determining the Effect of ABEP-HTurkey
-
Fundació Sant Joan de DéuRecruitingSchizophrenia Disorders | Treatment Resistant HallucinationsSpain
-
Pôle Saint HélierHopital La MusseCompleted
-
University of RoehamptonRecruitingDepressionUnited Kingdom